Epruvy (previously Ranibizumab Midas)
Active substance: ranibizumab
ranibizumab
Centralised EU authorisationActive
Marketing holder: Midas Pharma GmbH
Verified 2026-10-09 · EMA
Analogues in other countries- Source: EMA
- Countries with the substance registered: 3
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| RU 5 |
|
| US 11 |
|
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-5753-75ce-b282-16b0184889c9,01a120c3-81b2-71bb-a3f0-1a9e6ae1d7b6,01a120c3-8ec1-72d6-9e5c-f89d28751bb2,01a120c3-c512-730a-b8c5-1f8d268f76fe,01a120c6-56d1-71a6-bc18-ba6fa6dbc8dc;count=5 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a1208d-a08f-7733-8b11-29de61cf7869,01a1208f-3230-772b-97ce-25f110e738d6,01a12092-7af3-7f92-a7b0-89be97977ad1,01a12093-93a3-71c2-8cdf-a171b1dff12c,01a12093-93a7-73c7-ad05-5a6aab21c9de;count=11 · valid from 2026-10-09 · verified 2026-10-09
- Registration number
- EMEA/H/C/006528
- Registration status
- Active
- ATC code
- S01LA04
- product · EMA · EMEA/H/C/006528 · Verified 2026-10-09
- registration_status · EMA · EMEA/H/C/006528 · Verified 2026-10-09
- ingredients.0 · EMA · EMEA/H/C/006528 · Verified 2026-10-09